5,457 results match your criteria Overactive Bladder - Treatment


The utility of vaginal erbium: YAG laser in the treatment of overactive bladder syndrome is in need of confirmation.

Authors:
Senol Tonyali

World J Urol 2019 Apr 16. Epub 2019 Apr 16.

Turkiye Yuksek Ihtisas Training and Research Hospital Department of Urology, University of Health Sciences, Altındag, 06230, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02694-xDOI Listing

Gentle perineal skin stimulation for control of nocturia.

Anat Rec (Hoboken) 2019 Apr 12. Epub 2019 Apr 12.

Department of Autonomic Neuroscience, Tokyo Metropolitan Institute of Gerontology, Tokyo 173-0015, Japan.

One of the major causes of nocturia is overactive bladder (OAB). Somatic afferent nerve stimuli are used for treating OAB. However, clinical evidence for the efficacy of this treatment is insufficient due to the lack of appropriate control stimuli. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ar.24135DOI Listing

Primary Care Physician Perceptions of Female Pelvic Floor Disorders.

Hawaii J Med Public Health 2019 Apr;78(4):132-136

Department of Obstetrics, Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI.

Primary care physicians (PCPs) play a major role in patient access to appropriate health care. This study examines PCPs' perceptions and management of female pelvic floor disorders. Surveys were mailed to family medicine and internal medicine physicians associated with the Hawai'i Medical Service Association. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452021PMC
April 2019
1 Read

Concomitant primary ovarian paraganglioma neuroendocrinal differentiated urothelial tumor in a BOTOX-injected bladder: A case report.

Int J Surg Case Rep 2019 Mar 28;57:122-125. Epub 2019 Mar 28.

Urology Department, Urology and Nephrology Center, Mansoura University, Egypt.

Introduction: There is no reported data for patients with malignant bladder Botox injection related outcomes. Herein, we reported effect of Botox injection in case of BCG cystitis. In addition, reporting of rare incidence of both primary neuroendocrine differentiation of bladder tumor and primary ovarian paraganglioma post cystectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2019.03.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447811PMC
March 2019
1 Read

Relationship between Lower Urinary Tract Dysfunction and Clinical Features in Chinese Parkinson's Disease Patients.

Parkinsons Dis 2019 5;2019:6820937. Epub 2019 Mar 5.

Department of Neurology, Shengjing Hospital, Affiliated Hospital of China Medical University, No. 36 Sanhao Street, Shen Yang 110004, China.

Background: Lower urinary tract (LUT) dysfunction is very common in Parkinson's disease (PD) patients. However, the number of studies conducted on LUT dysfunction and its related factors in Chinese PD patients is very limited, and there is no international consensus concerning the results.

Methods: This cross-sectional study enrolled 100 Chinese PD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/6820937DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425341PMC
March 2019
2 Reads

An external compress-release protocol induces dynamic elasticity in the porcine bladder: A novel technique for the treatment of overactive bladder?

Neurourol Urodyn 2019 Apr 4. Epub 2019 Apr 4.

Department of Surgery/Division of Urology, Virginia Commonwealth University School of Medicine, Richmond, Virginia.

Introduction: Dynamic elasticity is an acutely regulated bladder material property through which filling and passive emptying produce strain softening, and active voiding restores baseline pressure. The aim of this study was to test the hypothesis that strain softening produced by filling-passive emptying is equivalent to that produced by compression-release in a porcine bladder model.

Methods/materials: Latex balloons and ex vivo perfused pig bladders were used for a series of alternating fill-passive emptying ("Fill") and external compress-release ("Press") protocols. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23992DOI Listing

Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies.

J Cell Mol Med 2019 Apr 3. Epub 2019 Apr 3.

Department of Experimental and Clinical Medicine, Histology and Embryology Research Unit, University of Florence, Florence, Italy.

Urothelium and Lamina Propria (LP) are considered an integrate sensory system which is able to control the detrusor activity. Complete supra-sacral spinal cord lesions cause Neurogenic Detrusor Overactivity (NDO) whose main symptoms are urgency and incontinence. NDO therapy at first consists in anti-muscarinic drugs; secondly, in intra-vesical injection of botulinum toxin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.14294DOI Listing
April 2019
1 Read

Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry.

Int Neurourol J 2019 Mar 31;23(1):69-74. Epub 2019 Mar 31.

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan.

Purpose: To identify factors predicting the presence of overactive bladder syndrome (OAB)-wet, compared with OAB-dry.

Methods: Between September 2007 and September 2013, the medical records of 623 women with OAB who completed a 3-day bladder diary and underwent urodynamic studies in a medical center were retrospectively reviewed. OAB-wet was diagnosed in patients who complained of at least one episode of urgency incontinence in the previous month; otherwise, OAB-dry was diagnosed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5213/inj.1836212.106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449656PMC

A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure.

Int Neurourol J 2019 Mar 31;23(1):30-39. Epub 2019 Mar 31.

Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Purpose: OnabotulinumtoxinA has demonstrated efficacy and safety in the treatment of urinary incontinence (UI) associated with neurogenic detrusor overactivity (NDO) and idiopathic overactive bladder (OAB); however, real-world evidence is limited. This postmarketing surveillance study aimed to assess the effectiveness and safety of onabotulinumtoxinA in Korean patients with UI associated with NDO or OAB with an inadequate response or intolerance to anticholinergics.

Methods: Patients received 200 U (NDO) or 100 U (OAB) of onabotulinumtoxinA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5213/inj.1836176.088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449655PMC
March 2019
1 Read

What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.

Arch Gynecol Obstet 2019 Apr 2. Epub 2019 Apr 2.

Department of Obstetrics and Gynecology, University Hospital Tübingen, Tübingen, Germany.

Purpose: To inform uro-gynecologists about the current standards and latest developments of sacral neuromodulation (SNM) in women with overactive bladder (OAB).

Methods: Literature search in the PubMed database for articles published between 1988 and 2019 on SNM for OAB in women.

Results: In total, 361 articles were identified and 51 articles retrieved for the review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05127-7DOI Listing
April 2019
2 Reads

The role of anticholinergic therapy based on the upoint system in the treatment of chronic prostatitis.

Arch Ital Urol Androl 2019 Mar 29;91(1):16-21. Epub 2019 Mar 29.

Acibadem Mehmet Ali Aydinlar University, Urology, Istanbul.

Objective: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common problem and severely impairs the quality of life (QoL). We aimed to investigate the effects of different treatment options on voiding symptoms and QoL in patients with urinary phenotype according to the UPOINT system. Matherial and methods: Ninety-six patients with NIH category II,III CP/CPPS were included in the study prospectively. Read More

View Article

Download full-text PDF

Source
https://www.pagepressjournals.org/index.php/aiua/article/vie
Publisher Site
http://dx.doi.org/10.4081/aiua.2019.1.16DOI Listing
March 2019
8 Reads

[Value of mirabegron in the treatment of overactive bladder].

Urologe A 2019 04;58(4):432-433

Klinik für Urologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburg Allee 160, 23538, Lübeck, Deutschland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00120-019-0916-3DOI Listing

A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.

Eur Urol 2019 Mar 25. Epub 2019 Mar 25.

Department of Urology, University Hospital of Rouen, Rouen, France.

Context: Current literature suggests that several pathophysiological factors and mechanisms might be responsible for the nonspecific symptom complex of overactive bladder (OAB).

Objective: To provide a comprehensive analysis of the potential pathophysiology underlying detrusor overactivity (DO) and OAB.

Evidence Acquisition: A PubMed-based literature search was conducted in April 2018, to identify randomised controlled trials, prospective and retrospective series, animal model studies, and reviews. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.02.038DOI Listing
March 2019
1 Read
13.938 Impact Factor

Are We missing out the role of oxytocin in overactive bladder syndrome?

Aging Male 2019 Mar 23:1-5. Epub 2019 Mar 23.

c Department of Urology & Andrology , Hamad General Hospital , Doha , Qatar.

Overactive bladder (OAB) is characterized by the storage symptoms of urgency with or without urgency incontinence. Although there is no clear cause of this idiopathic disease, overall prevalence of OAB symptoms in individuals aged 40 years old is more than 15%. Oxytocin, which is one of the most powerful contracting neuropeptide, was also shown to exhibit high intrinsic contractile activity on detrusor muscle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13685538.2019.1577376DOI Listing

Knowledge Gaps in Urologic Care of Female Spinal Cord Injury Patients.

Curr Urol Rep 2019 Mar 23;20(5):21. Epub 2019 Mar 23.

Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut St, Ste 1100, Philadelphia, PA, 19107, USA.

Purpose Of Review: We highlight the substantial gaps in knowledge on urologic care of female spinal cord injury (SCI) patients.

Recent Findings: Males account for approximately 80% of people living with SCI in developed nations. Although there is a robust body of literature in some aspects of urologic care of individuals with SCI, such as treatments for neurogenic detrusor overactivity, there are relatively few studies focusing specifically on females. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11934-019-0884-6DOI Listing
March 2019
1 Read

Pathophysiology of refractory overactive bladder.

Low Urin Tract Symptoms 2019 Mar 22. Epub 2019 Mar 22.

Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan.

Overactive bladder (OAB) is a common condition. The International Continence Society defines OAB as a symptom complex characterized by urgency with or without urge incontinence, usually with frequency and nocturia. The first-line treatment for OAB includes behavioral therapy, such as caffeine reduction, fluid intake modification, weight reduction, bladder training, and pelvic floor muscle training, as well as treatment with antimuscarinic or β -adrenoceptor agonist medications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/luts.12262DOI Listing
March 2019
7 Reads
0.543 Impact Factor

Urodynamics as a Prognosticator of Mirabegron Treatment Outcomes.

Gynecol Obstet Invest 2019 Mar 21:1-5. Epub 2019 Mar 21.

Stockholm Urogynecological Clinic, Stockholm, Sweden,

Aims: To determine if findings at urodynamics prognosticate improvements in overactive bladder symptoms among women receiving mirabegron treatment.

Methods: Before treatment, women completed a urodynamic investigation, a micturition diary and the Urinary Distress Inventory (UDI) with the irritative subscale UDIOAB. After 6 months mirabegron treatment, patients were clinically evaluated and completed the UDI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496606DOI Listing
March 2019
1 Read

Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration.

Rev Assoc Med Bras (1992) 2019 Feb;65(2):141-148

Central Hospital of Wenzhou, Wenzhou, Zhejiang, China.

Mirabegron is a kind of β3 adrenergic receptor agonist which is an effective drug for the treatment of overactive bladder. In this research, a UPLC-MS/MS method is developed and validated for the study of mirabegron pharmacokinetic in rats. A protein precipitation method is applied for sample preparation with acetonitrile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1806-9282.65.2.141DOI Listing
February 2019
2 Reads

Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.

Neurourol Urodyn 2019 Mar 19. Epub 2019 Mar 19.

Department of Urology, Moscow State University of Medicine and Dentistry, Moscow, Russia.

Background: The role of the selective antimuscarinic imidafenacin in Caucasian patients with overactive bladder (OAB) has not been previously assessed.

Objective: To evaluate the safety and efficacy of imidafenacin 0.2 mg vs tolterodine 4 mg per day in patients with OAB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23980DOI Listing

Respiratory dysfunction following initiation of mirabegron: A case report.

Respir Med Case Rep 2019 16;26:304-306. Epub 2019 Feb 16.

Northwestern University Feinberg School of Medicine, Division of Pulmonary and Critical Care Medicine, 240 East Huron Street, McGaw Pavilion, Suite M-349 Chicago, Illinois 60611, USA.

Background: Mirabegron, a β3 adrenergic receptor agonist, is FDA approved for treatment of overactive bladder. Approved in 2012 in the US, there have been no reports of any effects of mirabegron on pulmonary function.

Case Presentation: We report the case of a 65 year old male with a history of Parkinson's disease, OSA, and aspiration pneumonia presenting with subacute worsening dyspnea and found to have worsening restrictive ventilatory defect with a pattern consistent with neuromuscular weakness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2019.02.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402286PMC
February 2019
1 Read

Urogenital symptoms in mitochondrial disease: overlooked and undertreated.

Eur J Neurol 2019 Mar 18. Epub 2019 Mar 18.

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

Background: Bowel symptoms are well documented in mitochondrial disease. However, data concerning other pelvic organs is limited. We have undertaken a large, case-control study to determine the presence of lower urinary tract symptoms (LUTS) and sexual dysfunction in adults with genetically confirmed mitochondrial disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.13952DOI Listing
March 2019
1 Read

Treatment Satisfaction with Flexible-dose Fesoterodine in Patients with Overactive Bladder who were Dissatisfied with Previous Anticholinergic Therapy: A Multicenter Single-Arm Clinical Study.

Urol J 2019 Mar 18. Epub 2019 Mar 18.

Department of Urology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Republic of Korea.

Purpose: We investigated treatment satisfaction with flexible-dose fesoterodine in patients with overactive bladder (OAB) who were dissatisfied with previous anticholinergic therapy.

Materials And Methods: The subjects were prescribed fesoterodine 4 mg for 4 weeks and fesoterodine 4 mg or 8 mg for another 8 weeks. The primary end point of this study was patients' satisfaction after 12 weeks of fesoterodine treatment on a five-point Likert scale. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22037/uj.v0i0.4650DOI Listing
March 2019
1 Read

[Results and compliance of transcutaneous tibial nerve stimulation on overactive bladder syndrome in patients with Parkinson's disease. Retrospective Study.]

Prog Urol 2019 Mar 12. Epub 2019 Mar 12.

Hôpital Henry-Gabriel, 69230 Saint Genis-Laval, France. Electronic address:

Purpose: To investigate efficiency and tolerance of transcutaneous tibial nerve stimulation (TNS) in the overactive bladder syndrome in patients with Parkinson's disease (PD), and to identify predictive factors for compliance.

Methods: We conducted a retrospective monocentric study with a cohort of 17 patients with PD who have used TNS for an overactive bladder syndrome. The efficiency of the treatment was evaluated on the clinical improvement felt (rated out of ten). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.purol.2019.02.006DOI Listing
March 2019
1 Read

Effects of a combination of herbal extracts (modified Ojayeonjonghwan (Wuzi Yanzong wan)) on partial urethral obstruction-induced detrusor overactivity in rats: impact on the nitric oxide pathway and oxidative stress.

BMC Complement Altern Med 2019 Mar 14;19(1):64. Epub 2019 Mar 14.

Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Background: We investigated the effects of a berry mixture formula (modified Ojayeonjonghwan (Wuzi Yanzong Wan, MO formula) on detrusor overactivity (DO).

Methods: The MO formula consisted of 5 seeds obtained from 5 types of berry plants. Twenty-four Sprague-Dawley rats were randomly assigned to four groups: sham-operated (control), partial urethral obstruction-induced DO (DO group), 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12906-019-2467-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419416PMC
March 2019
2 Reads

Using a checklist to increase the effectiveness of behavioral therapy for overactive bladder: A prospective randomized controlled trial.

Neurourol Urodyn 2019 Apr 14;38(4):1152-1159. Epub 2019 Mar 14.

Department of Urology, Medical Science University, Ankara Training and Research Hospital, Ankara, Turkey.

Aim: To evaluate the benefits of a newly established checklist form of behavioral therapy for overactive bladder (OAB).

Methods: Of a total of 180 patients suffering eight or more micturitions, two or more nocturia, seven or more urgency, or four more urinary urgency incontinence (UUI) episodes per day according to a 3-day bladder diary, 155 were randomly divided into four groups. Group I (n = 29) patients were instructed to apply only behavioral therapy as a written guideline and group II (n = 27) patients were instructed to apply behavioral therapy with a written checklist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23974DOI Listing

β -Adrenoceptors in the normal and diseased urinary bladder - what are the open questions?

Br J Pharmacol 2019 Mar 14. Epub 2019 Mar 14.

Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany.

β -Adrenoceptor (β -AR) agonists are used in the treatment of overactive bladder syndrome (OAB). Although the relaxant response to adrenergic stimulation in human detrusor smooth muscle cells is mediated mainly via β -AR s, the plasma concentrations of the therapeutic dose of mirabegron, the only clinically approved β -AR agonist, are considerably lower than the EC for causing direct relaxation of human detrusor, suggesting the mechanism of action other than direct relaxation of detrusor smooth muscle. However, the site and mechanism of action of β -AR agonists in the bladder have not been firmly established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.14658DOI Listing

Does successful treatment of overactive bladder improve co-morbidities in patients with nocturia?

Australas J Ageing 2019 Mar 13. Epub 2019 Mar 13.

Department of Medicine and Aged Care, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Objective: To investigate whether treatment of overactive bladder (OAB), one comorbidity of nocturia, could reduce waking to void and improve other co-existing symptoms.

Methods: A prospective cohort study was conducted at Royal Melbourne Hospital. Participants received 12 weeks of standard treatment, including lifestyle interventions and pharmacotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajag.12644DOI Listing
March 2019
1 Read

Blebbistatin reveals beneficial effects on the cystometric parameters in an animal model of detrusor overactivity.

Naunyn Schmiedebergs Arch Pharmacol 2019 Mar 9. Epub 2019 Mar 9.

Chair and Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.

The aims of the study were to determine the effectiveness of blebbistatin (BLEB) on detrusor overactivity (DO) in an animal model induced by retinyl acetate (RA) and, because of potential urothelial permeability, to evaluate the degenerative impact of BLEB on the urothelium. Three days after RA instillation into the urinary bladder, BLEB was administered into the bladder and immediately after cystometric assessment was performed. Furthermore, Evans Blue extravasation into bladder tissue and urothelium thickness were measured. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00210-019-01640-3DOI Listing
March 2019
2 Reads

Effect of co-administration of BRL-37344 and tadalafil on reduction of overactive bladder symptoms after induction of detrusor overactivity in mice1.

Acta Cir Bras 2019 Feb 28;34(2):e201900205. Epub 2019 Feb 28.

PhD, Urologist, Department of Surgery, UFC, Fortaleza-CE, Brazil. Conception and design of the study, interpretation and analysis of data, critical revision, final approval.

Purpose: To evaluate the impact of the combination of BRL 37344 and tadalafil (TDF) on the reduction of overactive bladder (OB) symptoms.

Methods: Thirty mice were randomized into 5 groups (G) of 6 animals each. L-NAME was used to induce DO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0102-8650201900205DOI Listing
February 2019

Patient utilization survey of mirabegron prescribed for overactive bladder.

Investig Clin Urol 2019 Mar 26;60(2):114-119. Epub 2019 Feb 26.

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Purpose: Mirabegron, a β-adrenoreceptor agonist, is used to treat overactive bladder. The factors affecting persistence of mirabegron use or symptom improvement are not thoroughly known, but could be related to patient characteristics. Therefore, we evaluated persistence of medication use, symptom improvement, and quality of life among Finnish mirabegron users. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4111/icu.2019.60.2.114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397924PMC
March 2019
1 Read

Yoga for treating urinary incontinence in women.

Cochrane Database Syst Rev 2019 02 28;2:CD012668. Epub 2019 Feb 28.

Center for Integrative Medicine, University of Maryland School of Medicine, 520 W. Lombard Street, Baltimore, Maryland, USA, 21201.

Background: Urinary incontinence in women is associated with poor quality of life and difficulties in social, psychological and sexual functioning. The condition may affect up to 15% of middle-aged or older women in the general population. Conservative treatments such as lifestyle interventions, bladder training and pelvic floor muscle training (used either alone or in combination with other interventions) are the initial approaches to the management of urinary incontinence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD012668.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394377PMC
February 2019
2 Reads

Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.

BJU Int 2019 Feb 27. Epub 2019 Feb 27.

Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan.

Objectives: To evaluate the oncological and functional outcomes associated with selective tetramodal bladder-sparing therapy, comprising maximal transurethral resection of bladder tumour (TURBT), induction chemoradiotherapy (CRT), and consolidative partial cystectomy (PC) with pelvic lymph node dissection (PLND).

Materials And Methods: In the present study, 154 patients with non-metastatic muscle-invasive bladder cancer (MIBC), prospectively enrolled in the tetramodal bladder-preservation protocol, were analysed. After TURBT and induction CRT, patients showing complete remission were offered consolidative PC with PLND for the achievement of bladder preservation. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bju.14736
Publisher Site
http://dx.doi.org/10.1111/bju.14736DOI Listing
February 2019
6 Reads

Agonist-induced desensitisation of β -adrenoceptors: Where, when, and how?

Br J Pharmacol 2019 Feb 27. Epub 2019 Feb 27.

Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany.

β -Adrenoceptor agonists have proven useful in the treatment of overactive bladder syndrome, but it is not known whether their efficacy during chronic administration may be limited by receptor-induced desensitisation. Whereas the β -adrenoceptor has phosphorylation sites that are important for desensitisation, the β -adrenoceptor lacks these; therefore, it had been assumed that β -adrenoceptors are largely resistant to agonist-induced desensitisation. While all direct comparative studies demonstrate that β -adrenoceptors are less susceptible to desensitisation than β -adrenoceptors, desensitisation of β -adrenoceptors has been observed in many models and treatment settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.14633DOI Listing
February 2019
1 Read

Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.

World J Urol 2019 Feb 26. Epub 2019 Feb 26.

Urology Department, Beijing Hospital, National Center of Gerontology, No. 1 DaHua Road, Dong Dan, Beijing, 100730, People's Republic of China.

Purpose: The efficacy and safety of a novel remotely programmed BetterStim sacral neuromodulation (SNM) system was evaluated in patients with refractory overactive bladder (OAB) in a prospective, controlled, multicenter trial.

Methods: A total of 84 patients referred for SNM therapy from October 2015 to January 2018 were studied. Of the patients who qualified for implantation, 37 and 33 were randomly assigned to treatment and control groups, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02698-7DOI Listing
February 2019
3 Reads
2.666 Impact Factor

Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury : Anti-muscarinic drug effect on neurogenic bowel.

Spinal Cord 2019 Feb 25. Epub 2019 Feb 25.

Department of GI Physiology, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK.

Study Design: Prospective cohort study OBJECTIVES: We hypothesized that anti-muscarinic agents alter rectal compliance in SCI patients and that altered rectal compliance relates to bowel symptomatology. Our primary aim was to compare rectal compliance before and after the institution of anti-muscarinics (solifenacin and tolterodine) and an adrenoceptor agonist (mirabegron) in these patients. Additionally, we wanted to evaluate if anorectal manometry differed before and after use of anti-muscarinic agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41393-019-0263-7DOI Listing
February 2019
2 Reads

Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe.

Neurourol Urodyn 2019 Mar 22;38(3):981-989. Epub 2019 Feb 22.

Department of Urology, University Hospital Antwerpen, Edegem, Belgium.

Aim: To evaluate the impact of Vesomni/Urizia/Volutsa, a fixed-dose combination tablet containing 6 mg solifenacin (antimuscarinic) and 0.4 mg tamsulosin (α-blocker), on health-related quality of life (HRQoL) and treatment satisfaction in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in routine clinical practice.

Methods: EUROPA was a noninterventional study of men with LUTS/BPH not responding to monotherapy who were prescribed Vesomni in routine clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23944DOI Listing

Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.

Urol Int 2019 Feb 21:1-5. Epub 2019 Feb 21.

Department of Urology, Kyorin University School of Medicine, Tokyo, Japan.

Background: Treatment of overactive bladder (OAB) with antimuscarinic agents has been shown to improve depression and/or anxiety symptoms.

Objectives: The aim of this study was to evaluate the efficacy of mirabegron on OAB symptoms and its effects on depression and/or anxiety of treatment-naïve women with OAB.

Methods: Women treated with mirabegron were prospectively evaluated by the OAB symptom score and hospital anxiety and depression Scale before and at 4 and 8 weeks after treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497282DOI Listing
February 2019

The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis.

Urology 2019 Feb 18. Epub 2019 Feb 18.

Urologic Surgery, Vanderbilt University, Nashville, TN.

Objective: To compare the efficacy and safety of mirabegron and onabotulinumtoxinA in the management of treatment-experienced patients with overactive bladder.

Methods: The network meta-analysis was based on evidence from a systematic literature review of randomized controlled trials and a post-hoc analysis of treatment-experienced subpopulations from mirabegron studies.

Results: Nineteen trials described in 21 publications were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2019.02.005DOI Listing
February 2019
1 Read

Urinary nerve growth factor: a biomarker for overactive bladder in children? A meta-analysis and trail sequential analysis.

Pediatr Surg Int 2019 Feb 19. Epub 2019 Feb 19.

Department of Pediatric Surgery, Chengdu Women's and Children's Central Hospital of Chongqing Medical University, No. 1617, Riyue Avenue, Qinyang District, Chengdu, China.

Purpose: Based on previously two meta-analyses, urinary nerve growth factor (NGF) has emerged as one potentially noninvasive biomarker for overactive bladder (OAB) in adults. We performed this systematic review to explore if NGF is a biomarker for OAB in children.

Methods: A literature search was conducted in PubMed, Embase, Web of science and Cochrane Library. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00383-019-04447-8DOI Listing
February 2019
2 Reads

Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.

Neurourol Urodyn 2019 Mar 19;38(3):941-949. Epub 2019 Feb 19.

Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Aims: To compare the efficacy of fesoterodine or mirabegron add-on therapy for persistent overactive bladder (OAB) symptoms despite silodosin monotherapy in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, in both subjective and objective aspects.

Methods: A total of 120 patients with persistent OAB symptoms despite silodosin monotherapy were randomized to receive add-on therapy with fesoterodine (4 mg/day) or mirabegron (50 mg/day) for 12 weeks. At week 12, changes from baseline in patients' subjective symptoms and voiding/storage functions, as assessed using the International Prostate Symptom Score (IPSS), OAB symptom score (OABSS), and urodynamic studies, were compared between the groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nau.23935DOI Listing
March 2019
1 Read

Efficacy of fractional CO laser in the treatment of genitourinary syndrome of menopause in Latin-American Population: First Peruvian experience.

Lasers Surg Med 2019 Feb 19. Epub 2019 Feb 19.

Universidad Del Valle, Cali, Colombia.

Objective: This PUBA study aimed to assess the efficacy of fractional CO2 laser in the treatment of genitourinary syndrome of menopause (GSM).

Methods: GSM symptoms were assessed before, 1 month after the first session and 1 month after the third session of laser (3 sessions with a 30 days interval between them) in 60 women (median, interquartile range: 55, 49-69). Subjective (visual analog scale) and objective (Vaginal Health Index, VHIS; Vaginal Maturity Index/Frost Index; Spanish Overactive Bladder Questionnaire-Short Form, USMEX Spanish OAB-qSF and Female Sexual Function Index, FSFI) measures were used during the study period to assess CO2 fractionated laser treatment outcomes compared to baseline. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/lsm.23066
Publisher Site
http://dx.doi.org/10.1002/lsm.23066DOI Listing
February 2019
7 Reads

Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population.

J Pharm Biomed Anal 2019 Apr 7;167:155-160. Epub 2019 Feb 7.

Astellas Pharma Europe B.V., Leiden, The Netherlands.

Mirabegron is the first registered β3-adrenoceptor agonist for treatment of overactive bladder as an alternative to antimuscarinics. Previously four liquid chromatography-tandem mass spectrometry assays were published to determine mirabegron and eight metabolites (M5, M8, M11-M16) in human plasma. In order to support paediatric development, the assays were further optimized to reduce the required blood volume and increase the sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2019.02.007DOI Listing
April 2019
2 Reads

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer.

Clin Epidemiol 2019 23;11:133-143. Epub 2019 Jan 23.

Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden,

Introduction: One out of six adults has symptoms of overactive bladder (OAB). Antimuscarinic medication is the main pharmacological group used in the treatment of OAB. In preclinical studies, antimuscarinic compounds have been found to inhibit cell proliferation in lung cancer and colon cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CLEP.S186842DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350836PMC
January 2019
2 Reads

How durable is the effect of mirabegron in successfully-treated overactive bladder patients? Analysis of a multicentre study.

Ceska Gynekol Winter 2018;83(3):164-168

Objective: Many clinical studies indicate that pharmacologic treatment of overactive bladder (OAB) is considered effective and safe, but in real clinical practice a substantial proportion of patients discontinues the treatment. The reason for discontinuing the treatment most frequently reported is lack of efficacy and/or side effects. A further significant proportion of patients reports that they stopped the treatment because the symptoms disappeared or were resolved. Read More

View Article

Download full-text PDF

Source
February 2019
4 Reads

[Psychosomatic urology: how to treat chronic urological diseases].

Aktuelle Urol 2019 Apr 14;50(2):184-189. Epub 2019 Feb 14.

Ambulantes Rehabilitations-Zentrum für Urologie und Gynäkologie Heidelberg, Facharztpraxis für Urologie, Heidelberg.

In specialist urology clinics, 50 - 70 % of patients have chronic urological diseases such as recurrent urinary tract infections, a somatoform overactive bladder, adult and infantile enuresis, a chronic pelvic pain syndrome, and the psychosomatic form of post-prostatectomy incontinence. The 12-month prevalence of psychological disorders in the general adult population is 28 % 1. As many as 20 % of children and adolescents are found to have psychological abnormalities 2. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0834-5989
Publisher Site
http://dx.doi.org/10.1055/a-0834-5989DOI Listing
April 2019
8 Reads

[A role of fesoterodine in treatment of overactive bladder].

Urologiia 2018 Dec(6):155-162

Department of Urology of Federal State Budgetary Educational Institution of Higher Education A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.

The muscarinic receptors have been used as target in treatment of overactive bladder (OAB) for a long time. These patients have complaints of urgency, increased urinary frequency and nocturia, sometimes with urinary incontinence (involuntary urine leakage which is associated with abrupt and strong desire to void). Fesoterodine is a prodrug that is structurally and functionally associated with tolterodine and it is the novel drug for OAB treatment. Read More

View Article

Download full-text PDF

Source
December 2018

[Imidafenacin for treatment of overactive bladder and urgent urinary incontinence: the results of open-label multicenter randomized controlled clinical trial].

Urologiia 2018 Dec(6):20-25

FGBOU VO Pavlov First Saint Petersburg State Medical University of Minzdrav of Russia, Saint Petersburg, Russia.

Introduction: The analysis of the results of a multicenter, open, randomized comparative phase III clinical trial on the use of imidafenacin for treating patients with OAB was carried out. A clinical study was conducted according to GCP standards in 12 urological centers of the Russian Federation with the support of company AO "R-Pharm".

Materials And Methods: A total of 296 patients (men and women) aged from 18 to 65 years with OAB and urgent urinary incontinence were included in the study. Read More

View Article

Download full-text PDF

Source
December 2018